Brokers Issue New Targets On Sorrento Therapeutics, Inc. (SRNE)

Paterniano Del Favero
Agosto 24, 2017

PWE's SI was 11.45M shares in August as released by FINRA. 0 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data. The SI to Penn West Petroleum Limited New's float is 2.38%. The stock assembled a motion of -2.86% as of a recent closing trade. Manufacturers Life Company The owns 19,619 shares or 0% of their USA portfolio. It has underperformed by 18.29% the S&P500. The stock of Sorrento Therapeutics Inc (NASDAQ:SRNE) has "Buy" rating given on Thursday, June 15 by H.C. Wainwright. Therefore 100% are positive. The analysts, on average, are forecasting a $7.16 price target, but the stock is already up 54.21% from its recent lows. If the $1.62 price target is reached, the company will be worth $6.51 million less. The rating was maintained by FBR Capital with "Buy" on Thursday, June 15. rean maintained the stock with "Buy" rating in Wednesday, November 25 report. As per Wednesday, July 29, the company rating was maintained by Brean Capital. The company was maintained on Thursday, June 15 by H.C. Wainwright. Oppenheimer maintained the shares of SRNE in report on Tuesday, August 22 with "Buy" rating.

12/15/2014 - Sorrento Therapeutics, Inc. had its "buy" rating reiterated by analysts at Aegis Capital. On Tuesday, December 22 the stock rating was initiated by FBR Capital with "Outperform". The company was initiated on Monday, December 7 by H.C. Wainwright. The stock of Sorrento Therapeutics Inc (NASDAQ:SRNE) has "Buy" rating given on Monday, August 3 by MLV. Rodman & Renshaw reinitiated it with "Buy" rating and $45.0 target in Monday, December 7 report. The company has market cap of $4.72 billion. The Firm operates a portfolio of opportunities with an oil position in the Cardium, Viking and Peace River areas of Alberta. In terms of a technical look around Sorrento Therapeutics, Inc. The company has market cap of $130.12 million. The Firm is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. The Company's primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It closed at $1.75 lastly. State Street holds 0% of its portfolio in Sorrento Therapeutics Inc (NASDAQ:SRNE) for 514,597 shares. It has underperformed by 90.01% the S&P500.

Since June 15, 2017, it had 2 buys, and 0 sales for $70,466 activity. The stock tapped a 52-week high of US$16.08 while the mean 12-month price target for the shares is US$16.69. Its down 0.59, from 1.75 in 2016Q3.

Sorrento Therapeutics, Inc. (NASDAQ:SRNE)'s earnings per share has been growing at a -30 percent rate over the past 5 year when average revenue increase was noted as 72.8 percent. Credit Suisse Ag reported 0% of its portfolio in Sorrento Therapeutics Inc (NASDAQ:SRNE). Ny State Common Retirement Fund holds 0% of its portfolio in Eclipse Resources Corp (NYSE:ECR) for 44,000 shares.

FT reports, The 2 analysts offering 12 month price targets for Sorrento Therapeutics Inc have a median target of 13.50, with a high estimate of 20.00 and a low estimate of 7.00. Wells Fargo & Mn accumulated 125,261 shares. Hightower owns 31,730 shares for 0% of their portfolio. Brean Capital maintained Sorrento Therapeutics Inc (NASDAQ:SRNE) rating on Wednesday, November 25. Commonwealth Of Pennsylvania School Empls Retrmt has invested 0.01% of its portfolio in Sorrento Therapeutics Inc (NASDAQ:SRNE). 10,000 are owned by First Republic Inv Management Inc. 107,743 are held by Morgan Stanley. Dimensional Fund Advsrs Lp stated it has 16,015 shares.

Sorrento Therapeutics, Inc. (SRNE) stock showed a turn of -4.23% in most recent week and accomplished -17.07% performance over the last one month.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Altre relazioni OverNewsmagazine

Discuti questo articolo